UGOELLA LIMITED

Company number 13586965 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

UGOELLA LIMITED - Analysis Report

Company Number: 13586965

Analysis Date: 2025-07-20 11:25 UTC

  1. Risk Rating: LOW
    UGOELLA LIMITED demonstrates a stable financial position with positive net current assets and net assets increasing to £31,210 as of August 2024. The company is compliant with filing deadlines and maintains a micro-entity reporting status, indicating a small-scale operation with limited obligations. There is no indication of insolvency risk or regulatory non-compliance.

  2. Key Concerns:

  • Limited financial scale: As a micro-entity with modest assets and single employee, the scope for operational resilience in adverse conditions is limited.
  • Absence of profitability or income statement data: The information provided lacks profit/loss figures, making it difficult to assess operational profitability or cash flow trends.
  • Concentration risk: The company operates in a niche SIC code (86900 - other human health activities) which may expose it to sector-specific regulatory or demand risks.
  1. Positive Indicators:
  • Positive net current assets and net equity improving year-on-year, suggesting prudent working capital management and capital retention.
  • No overdue accounts or confirmation statement filings, indicating good governance and regulatory compliance.
  • The company has remained active since incorporation in 2021, with consistent financial reporting and a stable single-employee structure, reflecting operational consistency.
  1. Due Diligence Notes:
  • Review the company’s income statement and cash flow statements to confirm profitability and liquidity beyond balance sheet snapshots.
  • Investigate the nature of current assets to assess liquidity quality (e.g., cash vs. receivables or inventory).
  • Confirm absence of contingent liabilities or off-balance-sheet obligations that may affect solvency.
  • Evaluate the company’s business model and market position within the human health activities sector to understand sustainability and growth prospects.
  • Validate director background and any related party transactions for governance transparency.

Perspective: Investment Risk Assessor · Model: gpt-4.1-mini · Generated 20 July 2025

Sign in to generate a free AI analysis of this company — no password needed, just an email link.